Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion Biosciences Spotlight 59

Fluxion Biosciences has launched its Spotlight 59 Oncology Panel, a next-generation sequencing-based assay designed for liquid biopsy analyses. Used in conjunction with Fluxion's IsoFlux Liquid Biopsy System, the new panel is a complete sample-to-answer assay for high sensitivity mutation detection of solid tumor cancers from blood samples, the company said. In allowing ultra-sensitive variant detection from low input quantities of DNA, the panel is also potentially useful not only for liquid biopsy samples like circulating tumor cells or cell-free DNA, but also other challenging sample types such as FFPE.

For liquid biopsies, the panel's high sensitivity, driven by a bioinformatics method called ERASE-Seq, allows sensitivity to 0.1 percent allele frequency with no false positives, Fluxion said. The panel uses a 277-amplicon design based on Swift Biosciences Accel-Amplicon chemistry, covers hotspots in 59 clinically-relevant oncology-related genes, and generates multiplex libraries compatible with Illumina sequencing platforms, without the need for complicated molecular barcodes. 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.